Henricus G Ruhe

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9575275/henricus-g-ruhe-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

6,970 82 127 35 h-index g-index citations papers 8,605 6.2 5.65 134 L-index avg, IF ext. papers ext. citations

#	Paper	IF	Citations
127	Charting brain growth and aging at high spatial precision <i>ELife</i> , 2022 , 11,	8.9	2
126	Efficacy and acceptability of next step treatment strategies in adults with treatment-resistant major depressive disorder: protocol for systematic review and network meta-analysis <i>BMJ Open</i> , 2022 , 12, e056777	3	
125	Suicidal ideation in remitted major depressive disorder predicts recurrence <i>Journal of Psychiatric Research</i> , 2022 , 151, 65-72	5.2	O
124	Negative cognitive schema modification as mediator of symptom improvement after electroconvulsive therapy in major depressive disorder <i>Journal of Affective Disorders</i> , 2022 , 310, 156-	161 ⁶	
123	Brain aging in major depressive disorder: results from the ENIGMA major depressive disorder working group. <i>Molecular Psychiatry</i> , 2021 , 26, 5124-5139	15.1	48
122	Molecular Imaging of Depressive Disorders 2021 , 85-207		0
121	Bipolar Disorders 2021 , 261-296		
120	The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trial. <i>Neuropsychopharmacology</i> , 2021 , 46, 1307-1314	8.7	11
119	Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 1031-1042	2.2	2
118	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. <i>World Journal of Biological Psychiatry</i> , 2021 , 22, 561-628	3.8	3
117	Impact of Comorbid Personality Disorders on Depression Treatment in Routine Outpatient Care. <i>American Journal of Psychotherapy</i> , 2021 , appipsychotherapy20200046	1.3	
116	Digital phenotyping and the COVID-19 pandemic: Capturing behavioral change in patients with psychiatric disorders. <i>European Neuropsychopharmacology</i> , 2021 , 42, 115-120	1.2	16
115	Antidepressant Discontinuation: In Need of Scientific Evidence. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 512-515	1.7	O
114	The relationship between dose and serotonin transporter occupancy of antidepressants-a systematic review. <i>Molecular Psychiatry</i> , 2021 ,	15.1	4
113	Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence. <i>Translational Psychiatry</i> , 2021 , 11, 37	8.6	3
112	Impact of Comorbid Personality Disorders on Depression Treatment in Routine Outpatient Care <i>American Journal of Psychotherapy</i> , 2021 , 74, 150-156	1.3	
111	Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study. <i>BJPsych Open</i> , 2021 , 8, e4	5	2

(2019-2020)

110	Can loss of agency and oppositional perturbation associated with antidepressant monotherapy and low-fidelity psychological treatment dilute the benefits of guideline-consistent depression treatment at the population level?. <i>European Psychiatry</i> , 2020 , 63, e89	6	2
109	Omega-3 Fatty Acid Supplementation for Perinatal Depression: A Meta-Analysis. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	12
108	Fatty acids and recurrence of major depressive disorder: combined analysis of two Dutch clinical cohorts. <i>Acta Psychiatrica Scandinavica</i> , 2020 , 141, 362-373	6.5	3
107	What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from the ENIGMA Bipolar Disorder Working Group. <i>Human Brain Mapping</i> , 2020 ,	5.9	21
106	Effectiveness of Emotional Memory Reactivation vs Control Memory Reactivation Before Electroconvulsive Therapy in Adult Patients With Depressive Disorder: A Randomized Clinical Trial. <i>JAMA Network Open</i> , 2020 , 3, e2012389	10.4	3
105	Distinct temporal brain dynamics in bipolar disorder and schizophrenia during emotion regulation. <i>Psychological Medicine</i> , 2020 , 50, 413-421	6.9	10
104	Use of selective serotonin reuptake inhibitors is associated with very low plasma-free serotonin concentrations in humans. <i>Annals of Clinical Biochemistry</i> , 2020 , 57, 59-63	2.2	3
103	A Pilot Study of Smartphone-Based Memory Bias Modification and Its Effect on Memory Bias and Depressive symptoms in an Unselected Population. <i>Cognitive Therapy and Research</i> , 2020 , 44, 61-72	2.7	2
102	Attentional control, rumination and recurrence of depression. <i>Journal of Affective Disorders</i> , 2019 , 256, 364-372	6.6	9
101	The decision tool unipolar depression (DTUD): a new measure to facilitate the early identification of patients with major depressive disorder in need of highly specialized care. <i>BMC Psychiatry</i> , 2019 , 19, 179	4.2	2
100	Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis. <i>BMJ Open</i> , 2019 , 9, e027574	3	15
99	Longitudinal evidence for a relation between depressive symptoms and quality of life in schizophrenia using structural equation modeling. <i>Schizophrenia Research</i> , 2019 , 208, 82-89	3.6	9
98	Design and methods of the Snonitoring outcomes of psychiatric pharmacotherapyS(MOPHAR) monitoring program - a study protocol. <i>BMC Health Services Research</i> , 2019 , 19, 125	2.9	4
97	Altered ability to access a clinically relevant control network in patients remitted from major depressive disorder. <i>Human Brain Mapping</i> , 2019 , 40, 2771-2786	5.9	24
96	Emotional Biases and Recurrence in Major Depressive Disorder. Results of 2.5 Years Follow-Up of Drug-Free Cohort Vulnerable for Recurrence. <i>Frontiers in Psychiatry</i> , 2019 , 10, 145	5	17
95	Predicting clinical course in major depressive disorder: The association between DM-TRD score and symptom severity over time in 1115 outpatients. <i>Depression and Anxiety</i> , 2019 , 36, 345-352	8.4	10
94	Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression. <i>Psychological Medicine</i> , 2019 , 49, 366-379	6.9	33
93	Tapering of SSRI treatment to mitigate withdrawal symptoms. <i>Lancet Psychiatry,the</i> , 2019 , 6, 561-562	23.3	14

92	Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz198	1	5
91	Impaired reward-related learning signals in remitted unmedicated patients with recurrent depression. <i>Brain</i> , 2019 , 142, 2510-2522	11.2	15
90	Decreased functional connectivity of the insula within the salience network as an indicator for prospective insufficient response to antidepressants. <i>NeuroImage: Clinical</i> , 2019 , 24, 102064	5.3	6
89	Metabolic Syndrome at an Outpatient Clinic for Bipolar Disorders: A Case for Systematic Somatic Monitoring. <i>Psychiatric Services</i> , 2019 , 70, 143-146	3.3	5
88	Cortisol, dehydroepiandrosterone sulfate, fatty acids, and their relation in recurrent depression. <i>Psychoneuroendocrinology</i> , 2019 , 100, 203-212	5	11
87	Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. <i>Lancet, The</i> , 2018 , 391, 1357-1366	40	1283
86	Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders. <i>Journal of Inherited Metabolic Disease</i> , 2018 , 41, 597-611	5.4	24
85	The measurement of cognitive reactivity to sad mood in patients remitted from major depressive disorder. <i>British Journal of Clinical Psychology</i> , 2018 , 57, 313-327	3.6	8
84	Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring. <i>Drug Safety</i> , 2018 , 41, 655-664	5.1	5
83	Antidepressants might work for people with major depression: where do we go from here?. <i>Lancet Psychiatry,the</i> , 2018 , 5, 461-463	23.3	12
82	Altered frontal-amygdala effective connectivity during effortful emotion regulation in bipolar disorder. <i>Bipolar Disorders</i> , 2018 , 20, 349-358	3.8	20
81	Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. <i>Molecular Psychiatry</i> , 2018 , 23, 932-942	15.1	340
80	A state-independent network of depressive, negative and positive symptoms in male patients with schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2018 , 193, 232-239	3.6	34
79	Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 1485-1489	2.8	21
78	Differential relations of suicidality in depression to brain activation during emotional and executive processing. <i>Journal of Psychiatric Research</i> , 2018 , 105, 78-85	5.2	10
77	Validity of the Maudsley Staging Method in Predicting Treatment-Resistant Depression Outcome Using the Netherlands Study of Depression and Anxiety. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	8
76	Person-fit feedback on inconsistent symptom reports in clinical depression care. <i>Psychological Medicine</i> , 2018 , 48, 1844-1852	6.9	2
75	Seeing the signs: Using the course of residual depressive symptomatology to predict patterns of relapse and recurrence of major depressive disorder. <i>Depression and Anxiety</i> , 2018 , 35, 148-159	8.4	17

(2016-2018)

74	Monitoring of somatic parameters at outpatient departments for mood and anxiety disorders. <i>PLoS ONE</i> , 2018 , 13, e0200520	3.7	3
73	AuthorsSResponse to Braillon's Comment on: "Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring". <i>Drug Safety</i> , 2018 , 41, 1417-1418	5.1	
72	A symptom network structure of the psychosis spectrum. Schizophrenia Research, 2017, 189, 75-83	3.6	42
71	Biological profiling of prospective antidepressant response in major depressive disorder: Associations with (neuro)inflammation, fatty acid metabolism, and amygdala-reactivity. <i>Psychoneuroendocrinology</i> , 2017 , 79, 84-92	5	18
70	Impact of deep brain stimulation of the ventral anterior limb of the internal capsule on cognition in depression. <i>Psychological Medicine</i> , 2017 , 47, 1647-1658	6.9	14
69	Availability of CYP2D6 genotyping results in general practitioner and community pharmacy medical records. <i>Pharmacogenomics</i> , 2017 , 18, 843-851	2.6	5
68	Associations Between Daily Affective Instability and Connectomics in Functional Subnetworks in Remitted Patients with Recurrent Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2017 , 42, 258	83 ⁸ 2 ⁷ 59:	2 ²¹
67	The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial. <i>Trials</i> , 2017 , 18, 558	2.8	20
66	Agreement between clinical and MINI diagnoses in outpatients with mood and anxiety disorders. Journal of Affective Disorders, 2017 , 221, 268-274	6.6	15
65	Neural response to alcohol taste cues in youth: effects of the OPRM1 gene. <i>Addiction Biology</i> , 2017 , 22, 1562-1575	4.6	12
64	Aberrant default-mode network-hippocampus connectivity after sad memory-recall in remitted-depression. <i>Social Cognitive and Affective Neuroscience</i> , 2017 , 12, 1803-1813	4	30
63	Personalized Feedback on Symptom Dynamics of Psychopathology: A Proof-of-Principle Study. Journal for Person-Oriented Research, 2017, 3, 1-10	1	41
62	The Dutch Measure for quantification of Treatment Resistance in Depression (DM-TRD): an extension of the Maudsley Staging Method. <i>Journal of Affective Disorders</i> , 2016 , 205, 365-371	6.6	33
61	Distinguishing medication-free subjects with unipolar disorder from subjects with bipolar disorder: state matters. <i>Bipolar Disorders</i> , 2016 , 18, 612-623	3.8	41
60	A power analysis for future clinical trials on the potential adverse effects of SSRIs on amygdala reactivity. <i>Frontiers in Biology</i> , 2016 , 11, 256-259		O
59	Visuospatial planning in unmedicated major depressive disorder and bipolar disorder: distinct and common neural correlates. <i>Psychological Medicine</i> , 2016 , 46, 2313-28	6.9	11
58	Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption. <i>Journal of Endocrinology</i> , 2016 , 229, 1-12	4.7	35
57	Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. <i>Translational Psychiatry</i> , 2016 , 6, e756	8.6	159

56	Medication Discrepancies at Outpatient Departments for Mood and Anxiety Disorders in the Netherlands: Risks and Clinical Relevance. <i>Journal of Clinical Psychiatry</i> , 2016 , 77, 1511-1518	4.6	5
55	Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. <i>BMJ Open</i> , 2016 , 6, e010919	3	105
54	Vulnerability for new episodes in recurrent major depressive disorder: protocol for the longitudinal DELTA-neuroimaging cohort study. <i>BMJ Open</i> , 2016 , 6, e009510	3	23
53	Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Treatment-Resistant Depression: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2016 , 73, 456-64	14.5	165
52	Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial. <i>British Journal of Psychiatry</i> , 2016 , 208, 366-73	5.4	41
51	Altered functional connectivity during self- and close other-reflection in patients with bipolar disorder with past psychosis and patients with schizophrenia. <i>Neuropsychologia</i> , 2016 , 93, 97-105	3.2	6
50	Long-term antidepressant use: a qualitative study on perspectives of patients and GPs in primary care. <i>British Journal of General Practice</i> , 2016 , 66, e708-19	1.6	33
49	Effects of methylphenidate during emotional processing in amphetamine users: preliminary findings. <i>Brain Imaging and Behavior</i> , 2015 , 9, 878-86	4.1	7
48	DHEAS and cortisol/DHEAS-ratio in recurrent depression: State, or trait predicting 10-year recurrence?. <i>Psychoneuroendocrinology</i> , 2015 , 59, 91-101	5	34
47	Decreased Resting-State Connectivity between Neurocognitive Networks in Treatment Resistant Depression. <i>Frontiers in Psychiatry</i> , 2015 , 6, 28	5	39
46	Erythrocyte fatty acid profiles and plasma homocysteine, folate and vitamin B6 and B12 in recurrent depression: Implications for co-morbidity with cardiovascular disease. <i>Psychiatry Research</i> , 2015 , 229, 992-8	9.9	14
45	Fatty acid metabolism and its longitudinal relationship with the hypothalamic-pituitary-adrenal axis in major depression: Associations with prospective antidepressant response. Psychoneuroendocrinology, 2015, 59, 1-13	5	28
44	State-Dependent Differences in Emotion Regulation Between Unmedicated Bipolar Disorder and Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2015 , 72, 687-96	14.5	56
43	Predicting the Naturalistic Course of Major Depressive Disorder Using Clinical and Multimodal Neuroimaging Information: A Multivariate Pattern Recognition Study. <i>Biological Psychiatry</i> , 2015 , 78, 278-86	7.9	62
42	Adding mindfulness-based cognitive therapy to maintenance antidepressant medication for prevention of relapse/recurrence in major depressive disorder: Randomised controlled trial. <i>Journal of Affective Disorders</i> , 2015 , 187, 54-61	6.6	28
41	Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. <i>Diabetes, Obesity and Metabolism</i> , 2015 , 17, 878-86	6.7	65
40	Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder. <i>Psychoneuroendocrinology</i> , 2015 , 52, 261-71	5	33
39	Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses. <i>Biomarkers in Medicine</i> , 2015 , 9, 277-97	2.3	47

38	Brain activation during self- and other-reflection in bipolar disorder with a history of psychosis: Comparison to schizophrenia. <i>NeuroImage: Clinical</i> , 2015 , 8, 202-9	5.3	27
37	Cognitive reactivity versus dysfunctional cognitions and the prediction of relapse in recurrent major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, e1306-12	4.6	32
36	The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design. <i>BMC Psychiatry</i> , 2014 , 14, 48	4.2	20
35	Striatal dopamine D2/3 receptor availability in treatment resistant depression. <i>PLoS ONE</i> , 2014 , 9, e113	16 ₁ 7	8
34	Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1787-97	11.6	485
33	Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. <i>Acta Psychiatrica Scandinavica</i> , 2014 , 130, 163-80	6.5	83
32	Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2014 , 221, 155-61	2.9	14
31	Neuroinflammation in bipolar disorder - A [(11)C]-(R)-PK11195 positron emission tomography study. <i>Brain, Behavior, and Immunity</i> , 2014 , 40, 219-25	16.6	147
30	Molecular Imaging of Depressive Disorders 2014 , 93-172		6
29	Neural correlates of dysfunctional emotion regulation in major depressive disorder. A systematic review of neuroimaging studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2013 , 37, 2529-53	9	294
28	Relationship between the hypothalamic-pituitary-adrenal-axis and fatty acid metabolism in recurrent depression. <i>Psychoneuroendocrinology</i> , 2013 , 38, 1607-17	5	44
27	Mood reactivity rather than cognitive reactivity is predictive of depressive relapse: a randomized study with 5.5-year follow-up. <i>Journal of Consulting and Clinical Psychology</i> , 2013 , 81, 508-17	6.5	36
26	Ala54Thr fatty acid-binding protein 2 (FABP2) polymorphism in recurrent depression: associations with fatty acid concentrations and waist circumference. <i>PLoS ONE</i> , 2013 , 8, e82980	3.7	14
25	Staging methods for treatment resistant depression. A systematic review. <i>Journal of Affective Disorders</i> , 2012 , 137, 35-45	6.6	133
24	Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression. <i>Psychoneuroendocrinology</i> , 2012 , 37, 892-902	5	76
23	Bimodal distribution of fatty acids in recurrent major depressive disorder. <i>Biological Psychiatry</i> , 2012 , 71, e3-5	7.9	8
22	Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study. <i>BMC Psychiatry</i> , 2012 , 12, 125	4.2	36
21	Statistical methodological issues in handling of fatty acid data: percentage or concentration, imputation and indices. <i>Lipids</i> , 2012 , 47, 541-7	1.6	46

20	Neurotransmitters and neuropeptides in depression. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 106, 107-36	3	20
19	Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 451-9	4.6	81
18	Prevalence of psychiatric disorders in patients with chronic solvent induced encephalopathy (CSE). <i>NeuroToxicology</i> , 2011 , 32, 916-22	4.4	16
17	Investigating serotonergic function using positron emission tomography: overview and recent findings. <i>Current Pharmaceutical Design</i> , 2010 , 16, 1979-89	3.3	11
16	Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology, 2009, 34, 999-1010	8.7	62
15	Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 841-9	8.8	78
14	Screening for depression in high-risk groups: prospective cohort study in general practice. <i>British Journal of Psychiatry</i> , 2009 , 194, 399-403	5.4	34
13	Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 67-76	1.9	39
12	Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 2168-74	15.4	30
11	Agranulocytosis and granulocytopenia associated with quetiapine. <i>Acta Psychiatrica Scandinavica</i> , 2008 , 104, 311-314	6.5	12
10	Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. <i>Molecular Psychiatry</i> , 2007 , 12, 331-59	15.1	549
9	Tolerability of amine uptake inhibitors in urologic diseases. Current Drug Safety, 2006, 1, 73-85	1.4	6
8	Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. <i>British Journal of Psychiatry</i> , 2006 , 189, 309-16	5.4	54
7	Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 1836-55	4.6	163
6	Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores. <i>Comprehensive Psychiatry</i> , 2005 , 46, 417-27	7.3	69
5	Review: Low dose tricyclic antidepressants may be effective for adults with acute depressive disorder. <i>Evidence-Based Mental Health</i> , 2003 , 6, 46	11.1	
4	Agranulocytosis and granulocytopenia associated with quetiapine. <i>Acta Psychiatrica Scandinavica</i> , 2001 , 104, 311-3; discussion 313-4	6.5	28
3	Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999 , 19, 617-24	9.4	297

LIST OF PUBLICATIONS

Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. *Diabetologia*, **1999**, 42, 926-31

10.3 507

Charting Brain Growth and Aging at High Spatial Precision

2